← ANALYST RATINGS · TIPRANKS

BioLife Solutions (BLFS): analyst forecast and price target

$38.61 +3.51% close 05.10.26 · market cap $1.9B · Healthcare · Medical - Instruments & Supplies
Price targets and ratings of

Analyst consensus

Hold

0 Buy7 Hold0 Sell

Ratings of 7 analysts in the last 3 months

12-month forecast

$31.00−19.7% downside

Based on 7 price targets given in the last 3 months, the average target is $31.00, the highest $31.00, the lowest $31.00. The average is −19.7% from the last price of $38.61.

$20.00$30.00$40.00Jan 26AprJulOctJan 27AprJulOctHigh$31.00Average$31.00Low$31.00
Highest target $31.00 Average target $31.00 Lowest target $31.00
AnalystFirmPrice target RatingUpsideAction Date Move vs SPY
Matt Hewitt★★★★★★★★★★#3011 · hits 47% · avg +4.1% Craig-Hallum — Hold — Reiterated 29.09.26on TipRanks Sep 30 05:45 +0.4%next day −0.7%
Thomas Flaten★★★★★★★★★★#1650 · hits 47% · avg +8.9% Lake Street $31.00 Hold −19.7% Reiterated 09.09.26on TipRanks 07:50 −0.8%next day +0.6% · 5 days +4.5%
Robert Wasserman★★★★★★★★★★#2200 · hits 44% · avg +9.2% Benchmark Co. — Hold — Downgrade 10.08.26on TipRanks 06:27 0.0%next day +0.8% · 5 days +2.4%
Brendan Smith★★★★★★★★★★#458 · hits 56% · avg +27.3% TD Cowen $31.00 Hold −19.7% Reiterated 07.08.26on TipRanks 10:46 +1.5%next day 0.0% · 5 days +0.8%
Steven Etoch★★★★★★★★★★#2413 · hits 86% · avg +59.3% Stephens $32.00 → $31.00−3.1% Hold −19.7% Downgrade 27.07.26on TipRanks 14:10 −0.7%next day +7.1% · 5 days +5.4%
Matthew Stanton, CFA★★★★★★★★★★#10524 · hits 43% · avg −10.9% Jefferies $30.00 → $31.00+3.3% Hold −19.7% Downgrade 23.07.26on TipRanks Jul 24 08:10 0.0%next day −2.7% · 5 days +2.4%
Yi Chen★★★★★★★★★★#10518 · hits 41% · avg −1.0% H.C. Wainwright $32.00 → $31.00−3.1% Hold −19.7% Downgrade 23.07.26on TipRanks Jul 24 08:10 0.0%next day −2.7% · 5 days +2.4%
Jason McCarthy★★★★★★★★★★#12398 · hits 30% · avg −13.6% Maxim Group — Hold — Downgrade 23.07.26on TipRanks Jul 24 08:10 0.0%next day −2.7% · 5 days +2.4%
Carl Byrnes★★★★★★★★★★#11765 · hits 37% · avg −4.0% Northland Securities $34.00 Buy −11.9% Reiterated 24.03.26on TipRanks 08:35 +3.1%next day +0.3% · 5 days −2.7%

The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included

Best analysts covering BioLife Solutions

TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.

Most accurate

3 months Carl Byrnes★★★★★★★★★★Northland Securities · #11765
Hits 37%132 of 360 Average return −4.0%
1 year Carl Byrnes★★★★★★★★★★Northland Securities · #11765
Hits 37%132 of 360 Average return −4.0%
2 years Carl Byrnes★★★★★★★★★★Northland Securities · #11765
Hits 37%132 of 360 Average return −4.0%

Most profitable

3 months Carl Byrnes★★★★★★★★★★Northland Securities · #11765
Hits 37%132 of 360 Average return −4.0%
1 year Carl Byrnes★★★★★★★★★★Northland Securities · #11765
Hits 37%132 of 360 Average return −4.0%
2 years Carl Byrnes★★★★★★★★★★Northland Securities · #11765
Hits 37%132 of 360 Average return −4.0%

How the average price target moved

The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $31.00 at a price of $38.85 (−20.2%); now: $31.00 at $38.61 (−19.7%).

$32.50$35.00$37.50Sep 15Oct 1Top analysts$31.00Average target$31.00Price$38.61

PriceAverage targetTop analysts’ target

Recommendation trend

05101514Oct 2515Nov17Dec14Jan 26312Feb611Mar69Apr46May18Jun167Jul310Aug12Sep6Oct

Strong BuyBuyHoldSell

Rating05.2606.2607.2608.2609.2610.26
Strong Buy411000
Buy686300
Hold00710126
Sell000000

Earnings and sales forecast

Next report: 05.11.26 (Q3 2026, date not confirmed)

Earnings per share

Next quarter’s EPS estimate — $0.05 (from $0.01 to $0.07). Last quarter: $0.91.

Sales

Next quarter’s sales estimate — $29M (from $29M to $30M). Last quarter: $28M.

Best top-analyst consensus in the sector · Healthcare

ASNDAscendis PharmaStrong Buy
AXGNAxoGen
ONCBeOne MedicinesStrong Buy
BDTXBlack Diamond TherapeuticsStrong Buy
RPRXRoyalty PharmaStrong Buy
About BioLife Solutions

BioLife Solutions, Inc. (BLFS) operates as a global provider of specialized bioproduction tools and services, primarily catering to the cell and gene therapy industry. Its market reach extends across the United States, Canada, Europe, the Middle East, Africa, and other international regions. The company's offerings are essential for various stages of biologic-based therapy development, spanning from foundational and applied research to large-scale commercial manufacturing. Key products include proprietary biopreservation media, such as HypoThermosol FRS and CryoStor, which are engineered to minimize delayed cell damage and death typically associated with preservation. Complementing these are the ThawSTAR products, an automated line of devices for thawing vials and cryobags, designed to precisely manage the heat and timing for optimal biologic material thawing. BLFS also provides innovative cloud-connected evo shipping containers for the passive storage and secure transport of temperature-sensitive biologics and pharmaceuticals. Additionally, its comprehensive range encompasses liquid nitrogen laboratory freezers, various cryogenic equipment and accessories, and specialized storage services for biological and pharmaceutical products. Products are distributed both directly to customers and through a network of third-party distributors. Established in 1987, BioLife Solutions, Inc. maintains its headquarters in Bothell, Washington.

Data from the stock’s TipRanks forecast page, read 10526 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗